system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Administration, Oral, Animals, Bronchoalveolar Lavage Fluid, Constriction, Dose-Response Relationship, Drug, Enzyme Inhibitors, Hemodynamics, Lung, Male, Mesenteric Artery, Superior, Methylene Blue, Rats, Reperfusion Injury, Respiration.
user
Does methylene blue attenuate lung injury after mesenteric artery clamping/unclamping? Context: This controlled, experimental study was designed to assess the effects of intratracheal and intravenous methylene blue on reperfusion lung injury following superior mesenteric artery clamping/unclamping. Superior mesenteric arteries of 144 anaesthetized adult male Wistar rats (n = 12/group) were clamped for 1 h. Ten minutes before unclamping, methylene blue or its vehicle was administered intratracheally or intravenously, followed by a 3 h-respiratory assessment and postexperimental assessment of survival. Intravenous 3 and 9 mg kg(-1) but not higher methylene blue doses, and intratracheal 6-mg kg(-1) but not lower doses, significantly (P < 0.05) reduced the 100% increase in plateau pressure, 30% reduction in PO(2)/FiO(2), fourfold augmented bronchoalveolar lavage-retrieved volume and the increased polymorphonuclear leukocytes/bronchoalveolar cells' ratio associated with unclamping of the superior mesenteric artery. Lung tissue polymorphonuclear leukocytes count, total xanthine oxidase activity and wet-to-dry-weight ratio were also normal in these dose-treated groups. These effective regimens were also associated with longer animal survival.
assistant
Intratracheal methylene blue mitigates lung reperfusion injury following superior mesenteric artery clamping/unclamping at a similar magnitude as an intravenous regimen. This finding is a novel potential use of methylene blue in vivo. Final Decision: yes